Lebanon, New Hampshire – June 8, 2017 – Avitide, Inc., the industry leader in the discovery, development andmanufactureof biopharmaceutical affinity purification solutions, today announced that Scott Kennedy and Karol Lacki havejoined the company’s management team.
“We are thrilled to work with Scott and Karol to grow Avitide’s business and accelerate the discovery and implementation of Avitide’s affinity purification technologies in our partners’ biomanufacturing facilities. As we look ahead, Scott will help ensure a strong foundation for financial operations, manage growth, and support theevaluation of future business opportunities that are integral to Avitide’s long-term success,” said Kevin Isett, Avitide’s CEO and Co-founder. “Karol is a well-regarded industry expert who will help shape Avitide’s strategy as we work with our valued biopharmaceutical partners to reduce the cost and complexity of biologics purification.”
Scott Kennedy comes to Avitide with extensive financial, accounting, M&A, and operational life science experience. Mr. Kennedy previouslyserved as Vice President and CFO of the $800M per year Life Sciences Solutions division of PerkinElmer, where he oversaw the global finance functions and provided operational and strategic support across its diverse businesses. During his 14 years at PerkinElmer, he held several positions including Vice President of Corporate Finance and had a prominent role in its M&A activities including the acquisitions of Caliper Life Sciences, CambridgeSoft and ViaCell. Before that, Mr. Kennedy worked at the accounting firm RSM for more than 10 years. Mr. Kennedy received a Bachelor’s of Accounting degree from the University of Minnesota Duluth.
Karol Lackibrings extensive experience in biopharmaceutical purification, mathematical modeling and continuous downstream processing. Prior to Avitide, Dr. Lacki led the Mathematical Modeling department at Novo Nordisk, Bagsvaerd,Denmark. Before joining Novo Nordisk in 2015, he spent 17 years at GE Healthcare R&D in Uppsala, Sweden, conducting research on the development of chromatography resins, modeling and optimization of separation processes. His research also included development of high throughput methods for designing and characterizingchromatogaphic separations, as well as the development of continuous chromatography concepts. In this role, he provided scientific support to various research and development projects in areas related to process engineering and chromatography media development. He was also responsible for customer collaborations at GE Healthcare R&D. Karol received his Bachelor and Master in Applied Science degree in Process and Chemical Engineering from the Warsaw Technical University, Poland, and his Ph.D. degree in Chemical Engineering from the University of Ottawa, Canada. Karol has published extensively in the field of process biotechnology and co-chaired several sessions/workshops at major biotechnology conferences, including the 2nd Integrated Continuous Bioprocessing conference. He is also the co-founder and co-chair of the non-profit conference seriesHigh Throughput Process Development.
Avitide discovers, manufactures and supplies molecule-specific biopharmaceutical affinity purification solutions with an industry-leading 3-month service timeline. Avitide’s proprietary affinity separation technology enables its partners to achieve faster bioprocess development timelines, reduced program risk, predictable commercial scalability, and lower cost of manufacturing for batch and continuous operations. Avitide’s high-resolution affinity resins can be designed to select and enrich for improved drug safety, potency, and quality attributes critical to controlling target product profiles and establishing biosimilarity. Avitide also delivers exclusive biomanufacturing intellectual property with its technologies. Avitide’s management team brings substantial expertise and a track record of success in commercializing innovative biopharmaceutical discovery and manufacturing technology platforms. Avitide is financed by premiere venture capital firms such as Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, SV Life Sciences, NeoMed Management, and Borealis Ventures.
For more information, contact email@example.com.
MacDougall Biomedical Communications